Operating – Talk Bio

Actionable Insights Powered by AI

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

14 hours ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline